<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113953</url>
  </required_header>
  <id_info>
    <org_study_id>405-201-00056</org_study_id>
    <nct_id>NCT05113953</nct_id>
  </id_info>
  <brief_title>A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets After Oral Administration in Adult Subjects With Binge Eating Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy of 2 doses of centanafadine&#xD;
      sustained-release (SR) (200 mg and 400 mg total daily dose [TDD]) compared with placebo in&#xD;
      adults with moderate to severe binge eating disorder (BED).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 8, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Number of Binge Eating Days per Week</measure>
    <time_frame>Baseline up to Week 8</time_frame>
    <description>Having a binge eating day is defined as a day with at least one binge eating episode.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Change (CGI-C) Score</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>CGI-C will be measured on a scale from 1-7 where a higher score indicates worse disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Yale-Brown Obsessive-Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Score</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Y-BOCS-BE will be measured on a 10-item scale with each item rated from 0-4 where a higher score indicates more extreme symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Four-Week Cessation from Binging</measure>
    <time_frame>Up to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Number of Binge Episodes per Week</measure>
    <time_frame>Up to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient Global Impression - Severity (PGI-S) Score</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>PGI-S will be measured on a scale from 1-7 where a higher score indicates more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression - Change (PGI-C) Score</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>PGI-C will be measured on a scale from 1-7 where a higher score indicates a more severe disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Score</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>SF-36v2 will be measured on a scale from 1-100 where a lower total score (created by combining PCS and MCS scores) indicates a lower health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Eating Disorder Examination Questionnaire - 7-Item Version (EDE-Q7) Total Score</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>EDE-Q7 will be measured on a 7 item scale from 0-6 where a higher score indicates a more severe outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Day 1 up to 7 days after last dose of study treatment (up to approximately 9 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Global Impression - Severity (CGI-S) Score</measure>
    <time_frame>Weeks 1, 2, 3, 4, 6, 8</time_frame>
    <description>CGI-S will be measured on a scale from 1-7 where a higher score indicates a more severe outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Binge-Eating Disorder</condition>
  <arm_group>
    <arm_group_label>Low Dose: 200 mg Total Daily Dose (TDD) of Centanafadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg TTD of centanafadine will be administered as 1x 100 mg tablet and 1 placebo tablet twice daily (BID) 4-6 hours apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose: 400 mg Total Daily Dose (TDD) of Centanafadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg TTD of centanafadine will be administered as 2x 100 mg tablets twice daily (BID) 4-6 hours apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered as 2 placebo tablets twice daily (BID) 4-6 hours apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Centanafadine</intervention_name>
    <description>Sustained-release oral tablets</description>
    <arm_group_label>High Dose: 400 mg Total Daily Dose (TDD) of Centanafadine</arm_group_label>
    <arm_group_label>Low Dose: 200 mg Total Daily Dose (TDD) of Centanafadine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Low Dose: 200 mg Total Daily Dose (TDD) of Centanafadine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult participants 18 to 65 years of age (inclusive) at the time of informed consent.&#xD;
&#xD;
          -  A primary diagnosis of binge eating disorder (BED), or is diagnosed at screening,&#xD;
             according to Diagnostic and Statistical Manual of Mental Disorders - 5th Edition&#xD;
             (DSM-5) criteria and confirmed by the Structured Clinical Interview for DSM-5 (SCID).&#xD;
&#xD;
          -  BED with a history of at least moderate severity.&#xD;
&#xD;
          -  A rating of 4 or higher on the Clinical Global Impression - Severity (CGI-S) at&#xD;
             screening and baseline.&#xD;
&#xD;
          -  Body mass index (BMI) of 18 to 45 kg/m^2, inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lifetime history of bulimia nervosa or anorexia nervosa.&#xD;
&#xD;
          -  Participation in a formal weight loss program within 3 months of screening or planning&#xD;
             to start a weight loss program during the trial.&#xD;
&#xD;
          -  History of bariatric surgery.&#xD;
&#xD;
          -  Montgomery-Asberg Depression Rating Scale (MADRS) score â‰¥ 18.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Otsuka Call Center</last_name>
    <phone>844-687-8522</phone>
    <email>OtsukaUS@druginfo.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Centanafadine</keyword>
  <keyword>Binge Eating Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Binge-Eating Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.</ipd_time_frame>
    <ipd_access_criteria>Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/</ipd_access_criteria>
    <ipd_url>https://clinical-trials.otsuka.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

